Weight-loss medications for overweight pets move closer to approval
Pharmaceutical firms are developing GLP-1-style treatments for dogs and cats as pet obesity rates climb worldwide.
Drugmakers are advancing weight-loss medications designed specifically for dogs and cats, opening a potential new front in the battle against pet obesity. The push mirrors the rapid growth of human GLP-1 agonists and reflects concern from veterinarians that excess weight is shortening the lives of millions of companion animals.
Why pet obesity is drawing attention
Rates of overweight dogs and cats have risen steadily in recent decades, driven by overfeeding, calorie-dense diets and reduced activity. Studies suggest that obesity can shorten a pet's lifespan and increase the risk of diabetes, joint disease and certain cancers. Veterinarians say the problem now rivals dental disease as one of the most common health concerns in clinical practice.
How the new drugs would work
Several pharmaceutical companies are exploring formulations that mimic the appetite-suppressing and metabolic effects of human GLP-1 medications such as semaglutide. Early research focuses on injectable and oral options tailored to canine and feline biology, with the goal of producing safe, long-term treatments rather than short-term fixes.
For pet owners, the trend sits alongside broader conversations about sustainable weight management for animals and people alike. Researchers have also questioned whether diets like keto may influence cancer risk, while trainers increasingly promote sustainable approaches beyond restrictive diets.
What owners can do now
Until any pet-specific drug is approved, veterinarians recommend evidence-based steps:
- Measure food portions with a calibrated cup or scale.
- Choose diets formulated for the pet's age, breed and activity level.
- Schedule regular weigh-ins and routine vet checkups.
Experts caution that any future medication would complement, not replace, proper nutrition and exercise. As with human treatments, cost, side effects and access are likely to shape adoption once products reach the market.